retatrutide clinical trial information Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a New Weight Loss Drug Retatrutide:
Description
10.3389/fmolb.2015.00074 Front
Very different results and very different timelines
Over time, the dosage may be gradually increased based on tolerance and results
While GLP-1 medications were originally developed to treat diabetes, the drugs have exploded for their weight-loss potential
Moreover, the dose used to treat T2DM and obesity may differ
